Savient Pharmaceuticals, Inc. (NASDAQ: SVNTE), an emerging specialty pharmaceuticals company focused on developing, manufacturing and marketing novel therapeutic products for unmet medical needs, announced today that it has requested that the Nasdaq Listing Qualifications Panel (the Panel) extend until January 19, 2006 the date by which the Company must file an amendment to its Form 10-K for the year ended December 31, 2004, including 2003, 2002 and 2001 prior period restatements, and extend until January 26, 2006 the date by which the Company must file an amendment to its Form 10-Q for the quarter ended March 31, 2005, as well as its initial Forms 10-Q for the quarters ended June 30, 2005 and September 30, 2005 in order to continue listing of the Company's securities on The Nasdaq National Market.
